SCHD Isn't Your Sole Choice — 2 Monthly ETFs Offering Superior Long-Term Returns
Schwab U.S. Dividend Equity ETF Overview: The Schwab U.S. Dividend Equity ETF (SCHD) offers a reliable 3.8% yield and has shown impressive historical performance with a 12.2% annualized return over the past decade, but it has faced challenges in a tech-driven market, gaining only 2.8% year-to-date.
Amplify CWP Enhanced Dividend Income ETF: This ETF combines high-quality dividend stocks with a covered call strategy, yielding 4.5% and delivering a 12.5% annualized return since inception, outperforming SCHD, especially in the current market with a 14.2% year-to-date gain.
WisdomTree U.S. Quality Dividend Growth Fund: Targeting high-quality growth stocks, this fund has achieved a 14.3% annualized return over the past decade and offers monthly dividends, although its yield is lower at 1.4%. It has capitalized on tech growth, posting an 11.2% gain year-to-date.
Investment Strategy and Portfolio Diversification: A balanced portfolio including SCHD, Amplify, and WisdomTree could yield around 3.5% while targeting annualized returns of 11% or better, with monthly dividends providing flexibility and compounding benefits, particularly in tax-advantaged accounts.
Trade with 70% Backtested Accuracy
Analyst Views on NVDA
About NVDA
About the author

- Bond Offering Scale: Nvidia is looking to raise at least $20 billion through a bond offering with maturities ranging from two to 30 years, which will provide the company with long-term funding to support future investment needs.
- Marketing Strategy: The bond offering will be marketed in seven tranches, indicating Nvidia's proactive approach to capital markets aimed at attracting a diverse investor base to optimize its financing structure.
- First Bond Offering: This marks Nvidia's first bond issuance since 2021, signaling a renewed activity in capital markets that could secure funding for its future expansion and R&D initiatives.
- Underwriter Lineup: Top investment banks including J.P. Morgan, Morgan Stanley, and Goldman Sachs will be involved in the bond offering, reflecting market confidence in Nvidia and recognition of its growth potential.
- Strong Market Demand: Wedbush Securities analyst highlighted that Nvidia's move to pitch Vera CPUs to Chinese clients is a “sensible” strategy amid tensions surrounding H200 GPUs, indicating robust demand for CPUs and contributing to a rise in Nvidia's stock price during premarket trading.
- Significant Order Potential: Nvidia anticipates $20 billion in revenue from Vera chip sales by the end of this fiscal year, showcasing strong potential in the Chinese market, particularly as a major Chinese cloud company plans to order over 300 servers.
- Overseas Testing Deployment: Chinese clients plan to initially deploy Vera chips in overseas data centers for testing, which not only reflects interest in the new technology but may also pave the way for Nvidia's further expansion in international markets.
- Strengthened Partnerships: The success of Vera chips represents additional content for TSMC and Arm, further solidifying Nvidia's position in the global semiconductor supply chain and enhancing its relationships with key partners.
- Morgan Stanley Bullish on Onto Innovation: Morgan Stanley initiates Onto Innovation with an overweight rating, citing potential upside to consensus estimates driven by its process control capabilities in both front-end and back-end operations, suggesting a favorable re-rating ahead.
- Needham Initiates Ceva as Buy: Needham launches coverage of Ceva with a Buy rating and a price target of $55, indicating a 70x P/E based on CY27 EPS estimates, as the company is positioned to benefit from AI advancements in the semiconductor sector.
- UBS Initiates Jade Biosciences as Buy: UBS rates Jade Biosciences as a Buy, highlighting its best-in-class potential, with expectations that the FDA's acceptance of shorter eGFR kidney function data will expedite enrollment in pivotal studies.
- Morgan Stanley Upgrades Ferrari: Morgan Stanley upgrades Ferrari to overweight from equal weight, raising the price target to $438, arguing that the current de-rating overstates brand risk and that the company’s wealth creation and product pipeline support a positive re-rating.
- Capital Expenditure Surge: Global semiconductor sales reached $791.7 billion in 2025 and are projected to approach $1 trillion in 2026, indicating strong demand for AI infrastructure development, creating market opportunities for companies like TechForce Robotics.
- Strategic Alliance Formation: TechForce has formed a strategic partnership with JJ Enterprise, focusing on AI infrastructure and pharmaceutical robotics, aiming to leverage both companies' technological strengths to enhance competitiveness in rapidly growing markets.
- Structural Demand Growth: The global laboratory automation market is expected to grow from approximately $9.2 billion in 2025 to over $20 billion by 2034, with a compound annual growth rate of about 9.4%, reflecting urgent demand for high-precision automation solutions.
- Wide Application of Automation Technologies: TechForce's robotics platform has successfully expanded beyond the service industry into pharmaceutical and laboratory automation, demonstrating its potential and adaptability across multiple sectors.
- Surge in Capital Expenditure: Global semiconductor sales hit $791.7 billion in 2025 and are projected to approach $1 trillion in 2026, indicating strong demand for AI infrastructure development, which is driving rapid growth for companies like TechForce Robotics.
- Formation of Strategic Alliance: TechForce has formed a strategic partnership with JJ Enterprise, focusing on AI infrastructure and pharmaceutical robotics, aiming to leverage both companies' technological strengths to enhance competitiveness in high-precision manufacturing and automation markets.
- Emerging Market Opportunities: The global laboratory automation market is expected to grow from approximately $9.2 billion in 2025 to over $20 billion by 2034, with a compound annual growth rate of about 9.4%, providing significant market potential for TechForce, especially in pharmaceuticals and biotechnology.
- Rising Demand for Automation: With labor shortages and increasing compliance requirements, intelligent automation has become essential in pharmaceuticals and high-precision industries, and TechForce's robotic solutions are well-positioned to meet this market demand.
- Stock Pullback Impact: Microsoft's stock has dropped 15% since the beginning of the month, primarily due to Broadcom's disappointing sales forecast, which has weakened investor confidence in AI stocks and could affect the company's short-term market performance.
- Market Value and Growth: With a market capitalization of $2.9 trillion, Microsoft has shown strong demand and sustained revenue growth potential, as its cloud computing business achieved a 40% year-over-year growth rate in the most recent quarter, despite facing challenges.
- AI Business Surge: Microsoft's AI business has surpassed an annual revenue run rate of $37 billion, with a growth rate of 123%, and nearly 90% of Fortune 500 companies have utilized its low-code tools, indicating the company's extensive application and market penetration in the AI sector.
- Long-Term Investment Opportunity: Despite short-term stock fluctuations, Microsoft trades at a forward earnings estimate of 23 times, attracting investor interest and indicating its long-term growth potential in AI and cloud computing, potentially representing a once-in-a-decade investment opportunity.











